OLFM3

Across TCGA pan-cancer cohorts, OLFM3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OLFM3 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OLFM3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OLFM3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

STAD, HNSC, and SKCM are the cancer types where OLFM3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
HNSC	DFS	Median	All	1.000	0.615	.023	9	view →
SKCM	OS	Median	All	0.470	0.792	<.001	7	view →
LIHC	DFS	Median	All	0.195	0.558	.012	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OLFM3–STAD (OS)

Open the STAD breakdown →